What is most important in our report is that, by employing pro-metastatic assays in vitro and in vivo, we have demonstrated for the first time that purinergic signaling may be an attractive target for small molecule antagonists of purinergic receptors to inhibit the metastatic spread of LC cells. Here, P2RY1 is linked to laryngotracheoesophageal cleft.